GANZIMMUN will fully implement the enhanced version of the innovative DNA biomarker-based screening product by the beginning of next year, taking advantage of the significant improvements in sample processing and usability that have set a new industry benchmark. Partners are particularly drawn to the enhanced features, such as the proprietary DNA stabilizing buffer that ensures reliable results despite varying sample volumes, and the streamlined collection devices that simplify at-home testing for users.
These innovations have drastically reduced the need for retesting, offering faster turnaround times for patients, with results available in just 2β3 days from sample arrival. This underscores the increasing role of complementary medicine in cancer prevention and early detection. A multidisciplinary team comprising more than employees processes approximately 5, laboratory orders per day under the leadership of the experienced laboratory physician, Dr.
Patrik Zickgraf. The comprehensive diagnostic service spectrum, which includes over 4, laboratory parameters, includes besides the basic analytics a huge amount of innovative tests such as the ColoAlert.
About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. To learn more, visit mainzbiomed. For investor inquiries, please contact info mainzbiomed.
These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
